Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities, 9467 [2016-04059]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 37 / Thursday, February 25, 2016 / Notices
It is further ordered that the request of
the U.S. Department of Justice, the
Federal Bureau of Investigation, the
Drug Enforcement Agency, and the U.S.
Marshals Service, IS HEREBY
GRANTED, to the extent set forth in this
Order.
It is further ordered that a copy of this
Order shall be sent by return receipt
requested to Ocean Technology Limited
at its last known addresses.
It is further ordered that a copy of this
Order, or a summary thereof, shall be
published in the Federal Register.
This Order is issued on delegated
authority under 47 CFR 0.51, 0.261, and
is effective upon release. Petitions for
reconsideration under section 1.106 of
the Commission’s rules, 47 CFR 1.106,
or applications for review under section
1.115 of the Commission’s rules, 47 CFR
1.115, may be filed within 30 days of
the date of the release of this Order.
Federal Communications Commission.
Denise Coca,
Chief, Telecommunications and Analysis
Division, International Bureau.
A. Federal Reserve Bank of San
Francisco (Gerald C. Tsai, Director,
Applications and Enforcement), 101
Market Street, San Francisco, California
94105–1579:
1. H Bancorp LLC, Irvine, California;
to merge with Hopkins Bancorp, Inc.,
Baltimore, Maryland, and thereby
indirectly acquire Hopkins Federal
Savings Bank, Baltimore, Maryland.
Upon acquisition, Hopkins Federal
Savings Bank will merge into Bay Bank,
FSB, Lutherville Timonium, Maryland,
a wholly-owned subsidiary of Bay
Bancorp, Inc.
In connection with this application,
Applicant also has applied to acquire to
acquire 51 percent of iReverse Home
Loans, LLC, Owings Mill, Maryland,
and thereby engage in activities related
to extending credit, pursuant to sections
225.28(b)(1) and (b)(2) of Regulation Y.
Board of Governors of the Federal Reserve
System, February 22, 2016.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2016–04059 Filed 2–24–16; 8:45 am]
BILLING CODE 6210–01–P
[FR Doc. 2016–03939 Filed 2–24–16; 8:45 am]
BILLING CODE 6712–01–P
FEDERAL TRADE COMMISSION
[File No. 151–0202]
Notice of Proposals To Engage in or
To Acquire Companies Engaged in
Permissible Nonbanking Activities
mstockstill on DSK4VPTVN1PROD with NOTICES
FEDERAL RESERVE SYSTEM
Lupin Ltd., Gavis Pharmaceuticals
LLC, and Novel Laboratories, Inc.;
Analysis To Aid Public Comment
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y, (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the notices must be received
at the Reserve Bank indicated or the
offices of the Board of Governors not
later than March 21, 2016.
AGENCY:
VerDate Sep<11>2014
18:07 Feb 24, 2016
Jkt 238001
ACTION:
Federal Trade Commission.
Proposed consent agreement.
The consent agreement in this
matter settles alleged violations of
federal law prohibiting unfair methods
of competition. The attached Analysis to
Aid Public Comment describes both the
allegations in the draft complaint and
the terms of the consent orders—
embodied in the consent agreement—
that would settle these allegations.
DATES: Comments must be received on
or before March 22, 2016.
ADDRESSES: Interested parties may file a
comment at https://ftcpublic.comment
works.com/ftc/lupingavisnovelconsent
online or on paper, by following the
instructions in the Request for Comment
part of the SUPPLEMENTARY INFORMATION
section below. Write ‘‘In the Matter of
Lupin Ltd., Gavis Pharmaceuticals LLC,
and Novel Laboratories, Inc.—Consent
Agreement; File No. 151–0202’’ on your
comment and file your comment online
at https://ftcpublic.commentworks.com/
ftc/lupingavisnovelconsent by following
the instructions on the web-based form.
If you prefer to file your comment on
paper, write ‘‘In the Matter of Lupin
Ltd., Gavis Pharmaceuticals LLC, and
SUMMARY:
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
9467
Novel Laboratories, Inc.—Consent
Agreement; File No. 151–0202’’ on your
comment and on the envelope, and mail
your comment to the following address:
Federal Trade Commission, Office of the
Secretary, 600 Pennsylvania Avenue
NW., Suite CC–5610 (Annex D),
Washington, DC 20580, or deliver your
comment to the following address:
Federal Trade Commission, Office of the
Secretary, Constitution Center, 400 7th
Street SW., 5th Floor, Suite 5610
(Annex D), Washington, DC 20024.
FOR FURTHER INFORMATION CONTACT: Kari
Wallace, (202–326–3085), Bureau of
Competition, 600 Pennsylvania Avenue
NW., Washington, DC 20580.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 6(f) of the Federal Trade
Commission Act, 15 U.S.C. 46(f), and
FTC Rule 2.34, 16 CFR 2.34, notice is
hereby given that the above-captioned
consent agreement containing a consent
order to cease and desist, having been
filed with and accepted, subject to final
approval, by the Commission, has been
placed on the public record for a period
of thirty (30) days. The following
Analysis to Aid Public Comment
describes the terms of the consent
agreement, and the allegations in the
complaint. An electronic copy of the
full text of the consent agreement
package can be obtained from the FTC
Home Page (for February 19, 2016), on
the World Wide Web, at https://www.ftc.
gov/os/actions.shtm.
You can file a comment online or on
paper. For the Commission to consider
your comment, we must receive it on or
before March 22, 2016. Write ‘‘In the
Matter of Lupin Ltd., Gavis
Pharmaceuticals LLC, and Novel
Laboratories, Inc.—Consent Agreement;
File No. 151–0202’’ on your comment.
Your comment—including your name
and your state—will be placed on the
public record of this proceeding,
including, to the extent practicable, on
the public Commission Web site, at
https://www.ftc.gov/os/public
comments.shtm. As a matter of
discretion, the Commission tries to
remove individuals’ home contact
information from comments before
placing them on the Commission Web
site.
Because your comment will be made
public, you are solely responsible for
making sure that your comment does
not include any sensitive personal
information, like anyone’s Social
Security number, date of birth, driver’s
license number or other state
identification number or foreign country
equivalent, passport number, financial
account number, or credit or debit card
number. You are also solely responsible
E:\FR\FM\25FEN1.SGM
25FEN1
]]>Agencies
[Federal Register Volume 81, Number 37 (Thursday, February 25, 2016)]
[Notices]
[Page 9467]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-04059]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Notice of Proposals To Engage in or To Acquire Companies Engaged
in Permissible Nonbanking Activities
The companies listed in this notice have given notice under section
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and
Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or
control voting securities or assets of a company, including the
companies listed below, that engages either directly or through a
subsidiary or other company, in a nonbanking activity that is listed in
Sec. 225.28 of Regulation Y (12 CFR 225.28) or that the Board has
determined by Order to be closely related to banking and permissible
for bank holding companies. Unless otherwise noted, these activities
will be conducted throughout the United States.
Each notice is available for inspection at the Federal Reserve Bank
indicated. The notice also will be available for inspection at the
offices of the Board of Governors. Interested persons may express their
views in writing on the question whether the proposal complies with the
standards of section 4 of the BHC Act.
Unless otherwise noted, comments regarding the notices must be
received at the Reserve Bank indicated or the offices of the Board of
Governors not later than March 21, 2016.
A. Federal Reserve Bank of San Francisco (Gerald C. Tsai, Director,
Applications and Enforcement), 101 Market Street, San Francisco,
California 94105-1579:
1. H Bancorp LLC, Irvine, California; to merge with Hopkins
Bancorp, Inc., Baltimore, Maryland, and thereby indirectly acquire
Hopkins Federal Savings Bank, Baltimore, Maryland. Upon acquisition,
Hopkins Federal Savings Bank will merge into Bay Bank, FSB, Lutherville
Timonium, Maryland, a wholly-owned subsidiary of Bay Bancorp, Inc.
In connection with this application, Applicant also has applied to
acquire to acquire 51 percent of iReverse Home Loans, LLC, Owings Mill,
Maryland, and thereby engage in activities related to extending credit,
pursuant to sections 225.28(b)(1) and (b)(2) of Regulation Y.
Board of Governors of the Federal Reserve System, February 22,
2016.
Michael J. Lewandowski,
Associate Secretary of the Board.
[FR Doc. 2016-04059 Filed 2-24-16; 8:45 am]
BILLING CODE 6210-01-P
